From Discovery to Remission: How Agentic AI Is Reshaping the Oncology Continuum
Agentic AI is transforming oncology by unifying fragmented cancer data across discovery, diagnosis, treatment and survivorship, enabling faster research, diagnosis and trial enrollment while improving patient outcomes.
Oncology research has shifted from data collection to actionable insights, with agentic AI systems now closing gaps across the cancer care continuum by reasoning across multistep workflows. Historically siloed genomic sequences, pathology images, clinical notes and wearable signals are being unified to support faster decision-making in high-stakes scenarios. Traditional AI answers single questions, but agentic AI plans and executes multiple steps autonomously, requiring a robust data foundation to function effectively in regulated clinical environments.
The first bottleneck in oncology research—siloed molecular and genomic data—is being addressed by agentic systems that traverse genomic, structural and literature data in a single reasoning chain. These systems surface viable drug candidates earlier and flag likely failures before lab work, reducing the $50 billion to $60 billion annual cost of failed oncology trials. By accelerating the path from hypothesis to viable compound, research teams gain more time to focus on the most promising opportunities.
Multimodal signals that previously never converged are now being processed by AI-powered imaging triage and digital pathology, compressing workflows from days to minutes. A large U.S. screening study found that an AI-supported workflow identified 21.6% more breast cancers than standard mammography review, reducing patient uncertainty during the diagnostic waiting period. Agentic systems now integrate imaging findings, biomarker results, EHR risk flags and family history to replace manual, sequential assembly and deliver faster diagnoses.
Tumor boards, long reliant on manual assembly of disparate data sources, are being transformed by agentic systems that gather genomic profiles, pathology, imaging and treatment histories automatically. These systems structure patient briefs, cross-reference trial eligibility and surface relevant materials before board meetings, reducing time pressure and enabling faster treatment decisions. Fragmented real-world data is also being unified to improve trial enrollment, with agentic workflows identifying eligible cohorts in near real time and modeling feasibility before trials launch.